Anti-VEGF agents such as aflibercept used in our study, through their anti-angiogenic effect, allow the resolution of indirect signs of retinal ischemia such as hemorrhages and decrease the parietal vascular diffusion of fluorescein but do not allow for reducing retinal non-perfusion areas. This evidence concerns the gene VEGFA and retinal ischemia.